CD44 and cancer: PRI-724 reduced drug resistance and CSC phenotypes in TNBC251 and downregulated Sox2 and CD44 expression.252 Moreover, the combination of PRI-724 with cisplatin synergistically suppressed cell growth.252 While preclinical models showed that this treatment can reverse therapy resistance by targeting CSCs,253,254 its function in cancer has not been clinically determined, and liver injury may be a possible serious adverse event.255